Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Observational 1 Interventional 1

Sponsor

Cancer Type

Conditions

CYP3A Phenotyping 1 Breast Neoplasms 1

Interventions

Cisplatin 3202 Cyclophosphamide 3195 Carboplatin 2977 Radiotherapy 2790 Paclitaxel 2718 Gemcitabine 2572 pembrolizumab 2385 Bevacizumab 2209 Docetaxel 2199 Fluorouracil 1851 Capecitabine 1833 Oxaliplatin 1742 Dexamethasone 1605 Nivolumab 1581 Doxorubicin 1501 Rituximab 1488 Magnetic Resonance Spectroscopy 1387 Etoposide 1346 Irinotecan 1248 Leucovorin 1226 Drug Therapy 1205 Cytarabine 1130 Pemetrexed 1076 fludarabine 1063 Specimen Handling 1017 Vincristine 964 Cetuximab 945 Trastuzumab 945 Prednisone 942 Lenalidomide 937

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

2 trials

Recent Start date Enrollment

CEF regimen × Clear all

NCT00593697 2015-03-06

SOLD

Finnish Breast Cancer Group

Phase 3 Completed

Breast Neoplasms

NCT01110291 2010-04-27

Docetaxel

University of Turku

CYP3A Phenotyping

Data powered by HemOnc (CC BY 4.0) Colophon ⚡